IMMUNOGEN PEPTIDES AND "EPIVAKEBOL" VACCINE AGAINST EBOLA FEVER WITH APPLICATION OF INDICATED PEPTIDES Russian patent published in 2017 - IPC A61K38/00 A61K39/39 A61P31/12 

FIELD: medicine.

SUBSTANCE: immunogen peptide used as a component of the vaccine against Ebola fever, characterized by the amino acid sequence PQSLTTKPGPDNSTHNTPVYKLDISE (SEQ ID NO: 1), containing the antigenic epitopes of the GP protein of the Ebola virus, which have an ability to induce the formation of virus neutralizing antibodies to protect against the development of Ebola fever, is obtained. The second immunogen peptide used as a component of the vaccine against Ebola fever is characterized by the amino acid sequence HHQDTGEESASSGKLGLITNTIAG (SEQ ID NO: 2) containing the antigenic epitopes of the GP protein of the Ebola virus. The group of inventions also relates to a vaccine comprising a peptide-immunogen mixture having the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2, wherein the said peptides in the mixture are conjugated to an immunogenic carrier and sorbed onto a pharmaceutically acceptable adjuvant.

EFFECT: application of this group of inventions allows to obtain such peptide immunogens which carry minimally necessary antigenic determinants for formation of a specific immune response and contain antigenic regions of the GP protein of the Ebola virus that are immunogenic and that induce protective immunity against Ebola infection.

5 cl, 4 tbl, 6 ex